Metabolic disorders and the risk of head and neck cancer: a protocol for a systematic review and meta-analysis ============================================================================================================== * Alexander Gormley * Charlotte Richards * Francesca Spiga * Emily Gray * Joanna Hooper * Barry G Main * Emma E Vincent * Rebecca C Richmond * Julian PT Higgins * Mark Gormley ## Abstract **Introduction** Head and neck cancer squamous cell carcinoma (HNSCC) is the 6th most common cancer internationally. Established risk factors include smoking, alcohol and presence of human papillomavirus (HPV). The incidence rate of new disease continues to rise, despite falls in alcohol consumption and a reduction in smoking, the rising rates are unlikely to be solely attributed to HPV status alone. Obesity and its associated conditions such as type 2 diabetes (T2D) are implicated in the risk and progression of a variety of cancers but there is paucity of evidence regarding its role in HNSCC. **Methods and analysis** A systematic review of cohort studies, reporting a risk of incident head and neck squamous cell carcinoma will be included. A systematic search strategy has been developed, multiple databases will be searched from January 1966, including Cochrane Library, OVID SP versions of Medline and EMBASE. The primary outcome will be incident HNSCC based on exposures of type 2 diabetes, obesity, dyslipidemia and hypertension as defined by the World Health Organisation (WHO). A combined risk effect across studies will be calculated using meta-analysis, although depending on the heterogeneity in study design, exposure and outcome reporting this may not be possible. **Ethics and dissemination** No ethical approval is required for this systematic review. The review will be published in a revelant peer-review journal and findings will be presented at scientific meetings in both poster and oral presentation form. **Registration details** This study has been registered with the international prospective register of systematic reviews (PROSPERO) with study registration number CRD42021250520. This protocol has been developed in accordance with the preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) guidance statement. **Strengths and limitations of this study** * *This systematic review will be the first to comprehensively review the literature and provide a meta-analysis of the effect of metabolic disorders and the risk of incident HNSCC*. * *The publication of this protocol provides a clear representation of the methods used in this review for transparency and to prevent future duplication*. * *This systematic review will be one of the first to pilot the The ROBINS-E tool (Risk Of Bias In Non-randomised Studies - of Exposures)*. * *Despite the metabolic disorders being described as separate entities, the authors recognise the potential for disease processes to be related*. * *Among cohort studies there is significant variability in terms of length of follow-up for the outcome of interest, HNSCC*. ## Introduction Head and neck squamous cell carcinoma (HNSCC), which includes cancer of the oral cavity, oropharynx and larynx, is the world’s 6th most common cancer, with the highest incidence in males and those over 70 years old.1 Established risk factors include smoking, alcohol and the human papillomavirus (HPV), which has mainly been linked to oropharyngeal cancer.2 Despite the significant reduction in smoking,3 and a fall in alcohol consumption,4 in the UK over the previous two decades, incidence rates of head and neck cancers have continued to rise by around a third.1 Given this potentially changing aetiology,2 further exploration of less well known risk factors is warranted to target prevention and identify patients with early disease. People living with obesity and associated conditions such as type 2 diabetes (T2D), have an increased risk of developing certain cancers (e.g. liver and pancreas), but the epidemiological evidence surrounding HNSCC is not conclusive.5, 6 Recent studies have demonstrated elevated glucose levels before or at the time of diagnosis, which may play a role in the pathogenesis and progression of cancer.7 Carcinogenesis in HNSCC is driven by diverse signalling pathways, however, little is known about the role of metabolism,8 despite metabolic reprogramming being a recognised hallmark of cancer.9 T2D is a common condition characterised by insulin resistance and hyperglycaemia, which results in whole body metabolic dysregulation.10 In 2015, the estimated worldwide diabetes prevalence for adults was predicted to rise to 642 million by 204011. In addition, public health strategies have not successfully addressed the current ‘obesity pandemic’.12-16 One large pooled analysis demonstrated a weak positive association between T2D and HNSCC (OR 1.09; 95% confidence interval (95%CI): 0.95-1.24), which was stronger amongst those who never smoked cigarettes (OR 1.59; 95%CI: 1.22-2.07).6 While obesity is a potent risk factor for T2D, the relationship between body mass index (BMI) and HNSCC is not straightforward, with both positive and inverse associations observed.17 Another study found that a positive association with BMI was only observed in never smokers.18 In the largest study to date, waist circumference (WC) and waist-to-hip ratio (WHR) were positively associated with higher HNSCC risk, regardless of smoking status.18 Metabolic syndrome has been described as a clustering of disorders including obesity, hypertension, hyperglycaemia and dyslipidemia. A moderate inverse association has been observed between metabolic syndrome and HNSCC (OR 0.81; 95%CI, 0.78-0.85), but again these results were modified by tobacco use.19 Treatment for these conditions using medications such as statins,20 or metformin,21 may also reduce the risk of developing HNSCC. Given the growing pandemic of metabolic disorders, understanding how these alterations affect the risk of carcinogenesis may identify those who are high risk. This could drive targeted prevention, earlier detection and perhaps the identification or repurposing of drug targets for treatment in HNSCC.22 ### Rationale The complex metabolic changes associated with T2D, obesity, dyslipidemia and hypertension may alter the risk of certain cancers, but the evidence for head and neck cancer is inconclusive. This study aims to identify, collate and synthesise all relevant studies including adult participants, to determine whether the risk of developing incident HNSCC is influenced by T2D, obesity, dyslipidemia and hypertension, using relevant effect measures (e.g., odds or risk ratios). Where available, we will further stratify by subsite (i.e., oral cavity, oropharynx and larynx), as well as by HPV status. ### Methods #### Research Question ‘Do metabolic disorders affect the risk of developing head and neck cancer?’ #### Study Design Randomised controlled trials are informative for assessing causal effects, however due to the nature of the exposures in this study, inclusion of this design are not feasible. Therefore, we will focus on observational (e.g., cohort studies) reporting the risk of metabolic disorders on incident head and neck squamous cell carcinoma. #### Eligibility criteria **Population**-participants over 18 years old, of either sex, from any ethnic background. **Exposures-** 1) type 2 diabetes, 2) obesity, 3) dyslipidemia and 4) hypertension. These will be collectively described as ‘metabolic disorders. **Comparison**-participants who have not been diagnosed with the aforementioned metabolic disorders. **Outcome**-incident head and neck squamous cell carcinoma. The study will report in line with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement and has been pre-registered on International Prospective Register of Systematic Reviews (PROSPERO) in 2021 (CRD42021250520). #### Search strategy A systematic search strategy (**Supplementary Table 1**) has been formulated by clinicians, scientific researchers and a specialist librarian for Surgery, Head & Neck and Medicine. Medical Subject Headings (MeSH) and keywords will be iteratively combined with the Boolean operators AND, OR and NOT. Multiple databases will be searched from January 1966, including Cochrane Library, OVID SP versions of Medline and EMBASE. Pre-print servers including medRxiv and bioRxiv will also be searched. In addition, the following electronic bibliographic databases will be searched: EThOS, Google Scholar, Open Grey and ClinicalTrials.gov, to identify articles from the grey literature and conference proceedings. extracted from the full-length articles will be reviewed to identify other publications of interest. Duplicate articles will be removed using Covidence©23. #### Data management The results from searches will be imported into Covidence© software, to improve reference management and workflow. This will also populate a PRISMA flow diagram.24 #### Data screening and extraction All titles and abstracts will be screened by two authors A.G. and C.R., with conflicts resolved by A.G., C.R. and M.G. Screening records and decisions will be kept in Covidence©. Data will be extracted from titles that meet the inclusion criteria (**Table 1**). The data extraction form (**Supplementary Table 2**) will be piloted using 5 included titles with A.G., C.R. and M.G. independently completing data extraction. If amendments are necessary they will be performed at this point, with consensus approval required prior to final use of the form. Subsequent to this, C.R. and M.G. will double data extract indepdently for each title, any disagreements will be discussed between A.G., C.R. and M.G. with consensus approval required. View this table: [Table 1.](http://medrxiv.org/content/early/2021/10/16/2021.10.14.21264986/T1) Table 1. Study selection criteria ### Disease definitions 1. The World Health Organization (WHO) defines T2D as a chronic disease that occurs when the body cannot effectively use the insulin it produces and is largely the result of excess body weight and physical inactivity. A diagnosis of T2D is defined as symptoms such as polyuria or polydipsia, plus:25, 26 * a random blood plasma glucose concentration ≥ 11.1 mmol/l or; * a fasting plasma glucose concentration ≥ 7.0 mmol/l (whole blood ≥ 6.1 mmol/l) or; * two hour plasma glucose concentration ≥ 11.1 mmol/l two hours after 75g anhydrous glucose in an oral glucose tolerance test (OGTT) or; * glycated haemoglobin (HbA1c) 6.5% or more (48 mmol/mol and above) 2. The World Health Organization (WHO) defines obesity as having: a body mass index (BMI) of 30 or above.27 3. Dyslipidemia is classified as serum total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), triglycerides, apolipoprotein B, or lipoprotein(a) concentrations above the 90th percentile, or high density lipoprotein cholesterol (HDL-C) or apolipoprotein concentrations below the 10th percentile for the general population.28 4. The World Health Organization (WHO) defines hypertension as:29 * a systolic blood pressure reading of ≥140 mmHg when recorded on two different days; and/or * a diastolic blood pressure readings on both days of ≥90 mmHg. A diagnosis of incident head and neck squamous cell carcinoma should be confirmed by histology by a trained pathologist. Cancer diagnosis and confirmation may be reported using the International Classification of Diseases (ICD) codes.30 Cancer cases for the disease of interest have the following ICD codes: oral cavity (C02.0-C02.9, C03.0-C03.9, C04.0-C04.9, C05.0-C06.9) oropharynx (C01.9, C02.4, C09.0-C10.9), hypopharynx (C13.0-C13.9), overlapping (C14 and combination of other sites) and 25 cases with unknown ICD code (other). With respect to HPV diagnosis, only high risk subtypes HPV16, 18, 31, and 33 will be included. These are should be detected using HPV-DNA via polymerase chain reaction (PCR) and/or in situ hybridization (ISH) examination, usually used in combination with immunohistochemistry for *p16*. ### Data analysis and synthesis The analysis and synthesis process will be performed in two phases. The first phase consists of estimating the effect of each metabolic disorder (T2D, obesity, dyslipidemia and hypertension) on incident HNSCC separately for each included study. Effects should be reported as odds (OR) or risk ratios (RR), with 95% confidence intervals or in a format that will enable us to calculate these. The second phase will focus on estimating the combined effect across studies using meta-analysis, using metafor software in R (R Core Team, version 4.0.3).31 The analysis will yield information about the heterogeneity of effects across studies, using Cochran’s Q test and Higgins’ I2 statistic. Due to the heterogeneity in study design, exposure definition and outcome reporting in the included studies, meta-analysis may not be reasonable. ### Subgroup analyses Where possible, we will stratify by oral, oropharyngeal and laryngeal subsite and by HPV-status as post-hoc analyses, to determine if effects seen are specific to a particular anatomical region or associated with specific tumour types. ### Risk of bias in studies Two authors will independently extract the relevant risk factor information during data extraction using a preliminary version of the Risk of Bias in Non-randomised Studies – of Exposures (ROBINS-E) tool ([https://www.bristol.ac.uk/population-healthsciences/centres/cresyda/barr/riskofbias/robins-e/](https://www.bristol.ac.uk/population-healthsciences/centres/cresyda/barr/riskofbias/robins-e/)).32 The ROBINS-E tool aims to assess the result of interest from an observational study for risk of bias, where that study is designed to assess the effect of exposure on outcome.32 Disagreements will be recorded and discussed with a third author for resolution. This assessment will be used in evaluating the strength of evidence from the included studies. ### Amendments Any amendments to the initial protocol will be included in an update to the PROSPERO record, including information on amendment type, reasoning and a timestamp. Deviation from this protocol will be described in the full systematic review paper. ## Supporting information Supplementary Table 2 [[supplements/264986_file02.xlsx]](pending:yes) PRISMA-P Checklist [[supplements/264986_file03.docx]](pending:yes) ## Data Availability This is a protocol for a systematic review where no primary data will be collected, the search strategy is included in the supplementary data for where the data for this systematic review will be obtained from. ## Dissemination This systematic review will be published in a relevant peer-reviewed journal and findings from this work may be presented at scientific meetings (both poster and oral presentations). ## Ethical approval No ethical approval is required for the conducting of this systematic review. ## Authors’ contributions AG and CR jointly contributed to the development of the protocol and the drafting, writing and editing of this manuscript. FS contributed to the development of this study and editing of the manuscript. JH contributed to the development of the search strategy. BM, EG, EV, RR and JPTH contributed to the development of this study. MG was responsible for conceptualising this study, drafting and editing this manuscript. All authors contributed to the development of the search strategy. All authors have approved and contributed to the final written manuscript. ## Funding statement A.G. is a National Institute for Health Research (NIHR) academic clinical fellow. F.S. was supported by a Cancer Research UK (C18281/A29019) programme grant (the Integrative Cancer Epidemiology Programme). E.E.V is supported by Diabetes UK (17/0005587). E.E.V is also supported by the World Cancer Research Fund (WCRF UK), as part of the World Cancer Research Fund International grant programme (IIG_2019_2009). R.C.R. is a de Pass VC research fellow at the University of Bristol. J.P.T.H supported by the NIHR Biomedical Research Centre at University Hospitals Bristol and Weston NHS Foundation Trust and the University of Bristol, the NIHR Applied Research Collaboration West at University Hospitals Bristol and Weston NHS Foundation Trust and is a National Institute for Health Research (NIHR) Senior Investigator. M.G. is currently supported by a Wellcome Trust GW4-Clinical Academic Training PhD Fellowship. This research was funded in part, by the Wellcome Trust [Grant number 220530/Z/20/Z]. For the purpose of Open Access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission. The views expressed in this publication are those of the author(s) and not necessarily those of Wellcome, NIHR, the NHS or Department of Health. ## Competing interests statement None declared View this table: [Supplementary Table 1.](http://medrxiv.org/content/early/2021/10/16/2021.10.14.21264986/T2) Supplementary Table 1. Search strategy View this table: [Supplementary Table 2.](http://medrxiv.org/content/early/2021/10/16/2021.10.14.21264986/T3) Supplementary Table 2. Data extraction table. Note separate table for each exposure (Obesity, Dyslipidaemia, Hypertension, Type 2 diabetes). ## Acknowledgements None to declare. ## Footnotes * * Joint first authors * Received October 14, 2021. * Revision received October 14, 2021. * Accepted October 16, 2021. * © 2021, Posted by Cold Spring Harbor Laboratory This pre-print is available under a Creative Commons License (Attribution 4.0 International), CC BY 4.0, as described at [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/) ## References 1. 1.Cancer Research UK (CRUK). Head and neck cancer statistics 2019 [cited 2019 11/04/2019]. Available from: [https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/head-and-neck-cancers#heading-Two](https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/head-and-neck-cancers#heading-Two) Accessed 13/09/2021 2019. 2. 2.Thomas SJ, Penfold CM, Waylen A, et al. The changing aetiology of head and neck squamous cell cancer: A tale of three cancers? Clin Otolaryngol 2018;43(4):999–1003. doi: 10.1111/coa.13144 [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1111/coa.13144&link_type=DOI) 3. 3.Office for National Statistics. Data for 1974 onwards: Office for National Statistics. Adult Smoking habits in Great Britain. 2020 [Available from: [https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/drugusealcoholandsmoking/datasets/adultsmokinghabitsingreatbritain](https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/drugusealcoholandsmoking/datasets/adultsmokinghabitsingreatbritain). Accessed 01/03/2021 2020. 4. 4.Office for National Statistics. Adult drinking habits in Great Britain 2017 [Available from: [https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/drugusealcoholandsmoking/datasets/adultdrinkinghabits](https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/drugusealcoholandsmoking/datasets/adultdrinkinghabits) Accessed 01/03/2021 2021. 5. 5.Wotton CJ, Yeates DG, Goldacre MJ. Cancer in patients admitted to hospital with diabetes mellitus aged 30 years and over: record linkage studies. Diabetologia 2011;54(3):527–34. doi: 10.1007/s00125-010-1987-2 [Published online First: 2010/12/01] [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1007/s00125-010-1987-2&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=21116605&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F10%2F16%2F2021.10.14.21264986.atom) 6. 6.Stott-Miller M, Chen C, Chuang SC, et al. History of diabetes and risk of head and neck cancer: a pooled analysis from the international head and neck cancer epidemiology consortium. Cancer Epidemiol Biomarkers Prev 2012;21(2):294–304. doi: 10.1158/1055-9965.EPI-11-0590 [Published online First: 2011/12/07] [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6NDoiY2VicCI7czo1OiJyZXNpZCI7czo4OiIyMS8yLzI5NCI7czo0OiJhdG9tIjtzOjUwOiIvbWVkcnhpdi9lYXJseS8yMDIxLzEwLzE2LzIwMjEuMTAuMTQuMjEyNjQ5ODYuYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9) 7. 7.Vilaseca I, Fuster G, Avilés-Jurado FX. The impact of diabetes in head and neck cancer. Curr Opin Otolaryngol Head Neck Surg 2020;28(2):107–11. doi: 10.1097/moo.0000000000000606 [Published online First: 2020/02/06] [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1097/moo.0000000000000606&link_type=DOI) 8. 8.Rego DF, Elias ST, Amato AA, et al. Anti-tumor effects of metformin on head and neck carcinoma cell lines: A systematic review. Oncol Lett 2017;13(2):554–66. doi: 10.3892/ol.2016.5526 [Published online First: 2017/03/31] [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.3892/ol.2016.5526&link_type=DOI) 9. 9.Hanahan D, Weinberg RA. Hallmarks of Cancer: The Next Generation. Cell 2011;144(5):646–74. doi: 10.1016/j.cell.2011.02.013 [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.cell.2011.02.013&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=21376230&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F10%2F16%2F2021.10.14.21264986.atom) [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000288007100007&link_type=ISI) 10. 10.Koivula RW, Heggie A, Barnett A, et al. Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: rationale and design of the epidemiological studies within the IMI DIRECT Consortium. Diabetologia 2014;57(6):1132–42. doi: 10.1007/s00125-014-3216-x [Published online First: 2014/04/04] [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1007/s00125-014-3216-x&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=24695864&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F10%2F16%2F2021.10.14.21264986.atom) 11. 11.Ogurtsova K, da Rocha Fernandes JD, Huang Y, et al. IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract 2017;128:40–50. doi: 10.1016/j.diabres.2017.03.024 [Published online First: 2017/04/25] [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.diabres.2017.03.024&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=28437734&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F10%2F16%2F2021.10.14.21264986.atom) 12. 12.Wolf AM, Colditz GA. Current estimates of the economic cost of obesity in the United States. Obes Res 1998;6(2):97–106. doi: DOI 10.1002/j.1550-8528.1998.tb00322.x [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1002/j.1550-8528.1998.tb00322.x&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=9545015&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F10%2F16%2F2021.10.14.21264986.atom) [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000074526400001&link_type=ISI) 13. 13.Dombrowski SU, Knittle K, Avenell A, et al. Long term maintenance of weight loss with non-surgical interventions in obese adults: systematic review and meta-analyses of randomised controlled trials. Bmj-Brit Med J 2014;348 doi: ARTN g2646 10.1136/bmj.g2646 [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6MzoiYm1qIjtzOjU6InJlc2lkIjtzOjE3OiIzNDgvbWF5MTRfNi9nMjY0NiI7czo0OiJhdG9tIjtzOjUwOiIvbWVkcnhpdi9lYXJseS8yMDIxLzEwLzE2LzIwMjEuMTAuMTQuMjEyNjQ5ODYuYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9) 14. 14.Gray LJ, Cooper N, Dunkley A, et al. A systematic review and mixed treatment comparison of pharmacological interventions for the treatment of obesity. Obes Rev 2012;13(6):483–98. doi: 10.1111/j.1467-789X.2011.00981.x [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1111/j.1467-789X.2011.00981.x&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=22288431&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F10%2F16%2F2021.10.14.21264986.atom) 15. 15.Yanovski SZ, Yanovski JA. Long-term Drug Treatment for Obesity A Systematic and Clinical Review. Jama-J Am Med Assoc 2014;311(1):74–86. doi: 10.1001/jama.2013.281361 [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1001/jama.2013.281361&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=24231879&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F10%2F16%2F2021.10.14.21264986.atom) [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000329161400020&link_type=ISI) 16. 16.Corbin LJ, Timpson NJ. Body Mass Index: Has Epidemiology Started to Break Down Causal Contributions to Health and Disease? Obesity 2016;24(8):1630–38. doi: 10.1002/oby.21554 [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1002/oby.21554&link_type=DOI) 17. 17.Maasland DH, van den Brandt PA, Kremer B, et al. Body mass index and risk of subtypes of head-neck cancer: the Netherlands Cohort Study. Sci Rep 2015;5:17744. doi: 10.1038/srep17744 [Published online First: 2015/12/05] [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1038/srep17744&link_type=DOI) 18. 18.Gaudet MM, Kitahara CM, Newton CC, et al. Anthropometry and head and neck cancer:a pooled analysis of cohort data. Int J Epidemiol 2015;44(2):673–81. doi: 10.1093/ije/dyv059 [Published online First: 2015/06/08] [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1093/ije/dyv059&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=26050257&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F10%2F16%2F2021.10.14.21264986.atom) 19. 19.Stott-Miller M, Chen C, Schwartz SM. Type II diabetes and metabolic syndrome in relation to head and neck squamous cell carcinoma risk: a SEER-Medicare database study. Cancer Epidemiol 2013;37(4):428–33. doi: 10.1016/j.canep.2013.03.006 [Published online First: 2013/04/09] [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.canep.2013.03.006&link_type=DOI) 20. 20.Kao LT, Hung SH, Kao PF, et al. Inverse association between statin use and head and neck cancer: Population-based case-control study in Han population. Head Neck-J Sci Spec 2019;41(5):1193–98. doi: 10.1002/hed.25501 [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1002/hed.25501&link_type=DOI) 21. 21.Yen YC, Lin C, Lin SW, et al. Effect of metformin on the incidence of head and neck cancer in diabetics. Head Neck 2015;37(9):1268–73. doi: 10.1002/hed.23743 [Published online First: 2014/05/08] [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1002/hed.23743&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F10%2F16%2F2021.10.14.21264986.atom) 22. 22.Ramteke P, Deb A, Shepal V, et al. Hyperglycemia Associated Metabolic and Molecular Alterations in Cancer Risk, Progression, Treatment, and Mortality. Cancers (Basel) 2019;11(9) doi: 10.3390/cancers11091402 [Published online First: 2019/09/25] [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.3390/cancers11091402&link_type=DOI) 23. 23.Covidence. Covidence - Better systematic review management 2021 [Available from: [https://www.covidence.org/](https://www.covidence.org/) Accessed 13/09/2021 2021. 24. 24.Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009;339:b2700. doi: 10.1136/bmj.b2700 [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6MzoiYm1qIjtzOjU6InJlc2lkIjtzOjE3OiIzMzkvanVsMjFfMS9iMjcwMCI7czo0OiJhdG9tIjtzOjUwOiIvbWVkcnhpdi9lYXJseS8yMDIxLzEwLzE2LzIwMjEuMTAuMTQuMjEyNjQ5ODYuYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9) 25. 25.World Health Organization. Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycaemia 2006 [Available from: [https://www.diabetes.org.uk/resources-s3/2017-09/Definition\_and\_diagnosis1111.pdf](https://www.diabetes.org.uk/resources-s3/2017-09/Definition_and_diagnosis1111.pdf) Accessed 01/03/2021 2021. 26. 26.World Health Organization. Use of Glycated Haemoglobin (HbA1c) in the Diagnosis of Diabetes Mellitus 2011 [Available from: [https://www.diabetes.org.uk/resources-s3/2017-09/Definition\_and_diagnosis1111.pdf](https://www.diabetes.org.uk/resources-s3/2017-09/Definition_and_diagnosis1111.pdf) Accessed 01/03/2021 2021. 27. 27.World Health Organization. Obesity and overweight 2021 [Available from: [https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight](https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight) Accessed 01/03/2021 2021. 28. 28.British Medical Journal. Hypercholesterolemia 2019 [Available from: [https://bestpractice.bmj.com/topics/en-us/170](https://bestpractice.bmj.com/topics/en-us/170) Accessed 28.03.2021 2021. 29. 29.Organization WH. Hypertension 2021 [Available from: [https://www.who.int/news-room/fact-sheets/detail/hypertension](https://www.who.int/news-room/fact-sheets/detail/hypertension) Accessed 13/09/2021 2021. 30. 30.Organization WH. International Statistical Classification of Diseases and Related Health Problems (ICD) 2021 [Accessed 13/09/2021 2021. 31. 31.Viechtbauer W. metafor: Meta-Analysis Package for R 2021 [Available from: [https://cran.r-project.org/web/packages/metafor/index.html](https://cran.r-project.org/web/packages/metafor/index.html) Accessed October 2021 October 2021. 32. 32.Bristol Uo. The ROBINS-E tool (Risk Of Bias In Non-randomized Studies - of Exposures) 2021 [Available from: [http://www.bristol.ac.uk/population-health-sciences/centres/cresyda/barr/riskofbias/robins-e/](http://www.bristol.ac.uk/population-health-sciences/centres/cresyda/barr/riskofbias/robins-e/) Accessed 13/09/2021 2021.